Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2020 · 10-Q
Revenue$108.00K$108.00K+140.0% vs Q1 2019 Net Income-$4.46M-$4.46MN/M vs Q1 2019 EPS Diluted-$0.21-$0.21N/M vs Q1 2019 Operating Income-$3,855,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,287,000N/M Margins · derivedOperating margin-3569.4%+5208.3 pt vs Q1 2019
Net margin-4132.4%+5640.9 pt vs Q1 2019
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end